These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 10523677)

  • 1. Adoptive therapy of canine metastatic mammary carcinoma with the human MHC non-restricted cytotoxic T-cell line TALL-104.
    Visonneau S; Cesano A; Jeglum KA; Santoli D
    Oncol Rep; 1999; 6(6):1181-8. PubMed ID: 10523677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors.
    Cesano A; Visonneau S; Jeglum KA; Owen J; Wilkinson K; Carner K; Reese L; Santoli D
    Cancer Res; 1996 Jul; 56(13):3021-9. PubMed ID: 8674057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of a human cytotoxic T-cell line (TALL-104) in brain tumor xenografts.
    Geoerger B; Tang CB; Cesano A; Visonneau S; Marwaha S; Judy KD; Sutton LN; Santoli D; Phillips PC
    Neuro Oncol; 2000 Apr; 2(2):103-13. PubMed ID: 11303619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicological and immunological evaluation of the MHC-non-restricted cytotoxic T cell line TALL-104.
    Cesano A; Visonneau S; Wolfe JH; Jeglum KA; Fernandez J; Gillio A; O'Reilly RJ; Santoli D
    Cancer Immunol Immunother; 1997 May; 44(3):125-36. PubMed ID: 9191872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of canine malignant histiocytosis with the human major histocompatibility complex nonrestricted cytotoxic T-cell line TALL-104.
    Visonneau S; Cesano A; Tran T; Jeglum KA; Santoli D
    Clin Cancer Res; 1997 Oct; 3(10):1789-97. PubMed ID: 9815565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of development of host immunity on the biodistribution of xenogeneic MHC non-restricted cytotoxic T cells: implications for adoptive cell therapy of cancer.
    Cesano A; Wortman JA; Pourdehnad M; Visonneau S; Mozley D; Bhatnagar A; Alavi A; Santoli D
    Int J Oncol; 1999 Feb; 14(2):233-44. PubMed ID: 9917497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia.
    Cesano A; Visonneau S; Pasquini S; Rovera G; Santoli D
    Cancer Res; 1996 Oct; 56(19):4444-52. PubMed ID: 8813139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TALL-104 cell therapy of human solid tumors implanted in immunodeficient (SCID) mice.
    Cesano A; Visonneau S; Santoli D
    Anticancer Res; 1998; 18(4A):2289-95. PubMed ID: 9703868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer.
    Visonneau S; Cesano A; Porter DL; Luger SL; Schuchter L; Kamoun M; Torosian MH; Duffy K; Sickles C; Stadtmauer EA; Santoli D
    Clin Cancer Res; 2000 May; 6(5):1744-54. PubMed ID: 10815893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy.
    Kruse CA; Visonneau S; Kleinschmidt-DeMasters BK; Gup CJ; Gomez GG; Paul DB; Santoli D
    Cancer Res; 2000 Oct; 60(20):5731-9. PubMed ID: 11059767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodistribution of human MHC non-restricted TALL-104 killer cells in healthy and tumor bearing mice.
    Cesano A; Visonneau S; Tran T; Santoli D
    Int J Oncol; 1999 Feb; 14(2):245-51. PubMed ID: 9917498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cells.
    Wright SE; Rewers-Felkins KA; Quinlin IS; Fogler WE; Phillips CA; Townsend M; Robinson W; Philip R
    Immunol Invest; 2008; 37(3):215-25. PubMed ID: 18389441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function.
    Liu C; Yu S; Zinn K; Wang J; Zhang L; Jia Y; Kappes JC; Barnes S; Kimberly RP; Grizzle WE; Zhang HG
    J Immunol; 2006 Feb; 176(3):1375-85. PubMed ID: 16424164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic carcinoma-specific immunotherapy using novel tumor specific cytotoxic T cells.
    Lei J; Wu Z; Jiang Z; Li J; Zong L; Chen X; Duan W; Xu Q; Zhang L; Han L; Ma Q; Wang Z; Zhang D
    Oncotarget; 2016 Dec; 7(50):83601-83610. PubMed ID: 27876704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding of the immunological heterogeneity of canine mammary carcinomas to provide immunophenotypic features of circulating leukocytes as clinically relevant prognostic biomarkers.
    Estrela-Lima A; Araújo MS; da Costa-Neto JM; Ribeiro LG; Damasceno KA; D'Assis MJ; Martins-Filho OA; Teixeira-Carvalho A; Serakides R; Cassali GD
    Breast Cancer Res Treat; 2012 Feb; 131(3):751-63. PubMed ID: 21448671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
    Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
    Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological aspects of mammary tumors in dogs and cats: a survey including own studies and pertinent literature.
    Rutten VP; Misdorp W; Gauthier A; Estrada M; Mialot JP; Parodi AL; Rutteman GR; Weyer K
    Vet Immunol Immunopathol; 1990 Nov; 26(3):211-25. PubMed ID: 2264285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human cytotoxic T-cells suppress the growth of spontaneous melanoma metastases in SCID/hu mice.
    Sabzevari H; Reisfeld RA
    Cancer Res; 1993 Oct; 53(20):4933-7. PubMed ID: 8402683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model.
    Liu LL; Smith MJ; Sun BS; Wang GJ; Redmond HP; Wang JH
    Ann Surg Oncol; 2009 May; 16(5):1403-11. PubMed ID: 19263173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice.
    Visonneau S; Cesano A; Torosian MH; Santoli D
    Clin Cancer Res; 1997 Sep; 3(9):1491-500. PubMed ID: 9815835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.